Jul 18 |
Is Adverum Biotechnologies Stock Outpacing Its Medical Peers This Year?
|
Jul 17 |
26-Week Interim Analysis of the LUNA Phase 2 Trial Update Call
|
Jul 17 |
Adverum Biotechnologies, Inc's (ADVM) 26-Week Interim Analysis of the LUNA Phase 2 Trial Update Transcript
|
Jul 17 |
Adverum posts mid-stage data for wet AMD candidate
|
Jul 17 |
Adverum Biotechnologies Presents Positive Ixo-vec Clinical Data from the 26-Week Interim Analysis of the LUNA Phase 2 Trial at the 2024 ASRS Annual Meeting
|
Jul 16 |
Wall Street Analysts Think Adverum Biotechnologies (ADVM) Could Surge 290.54%: Read This Before Placing a Bet
|
Jul 10 |
Adverum Biotechnologies to Host Webcast to Review Clinical Data from the 26-Week Interim Analysis of the Ongoing LUNA Phase 2 Trial in Wet AMD Being Presented at ASRS Annual Meeting
|
Jun 18 |
Adverum Biotechnologies to Participate in TD Cowen’s Genetic Medicines & RNA Summit
|
Jun 11 |
Adverum Biotechnologies Announces Appointments of Dr. Rabia Gurses Ozden as Chief Medical Officer and Dr. Szilárd Kiss as a Member of the Board of Directors
|
May 10 |
Adverum Biotechnologies Reports Q1 2024 Results: A Detailed Look at Financials and Pipeline Progress
|